A "groundbreaking" cancer treatment trial by Memorial Sloan Kettering shows immunotherapy alone can eliminate some tumors, offering patients an alternative to chemotherapy and surgery.

Rectosigmoid junction,” he said, referring to a zone where the rectum and colon meet. After surgery came chemotherapy. He did 10 rounds of infusions, 28 rounds of radiation and oral chemotherapy.

In all 49 rectal cancer patients, there was no evidence of cancer after immunotherapy. Of the 54 patients with other cancers, 35 saw all signs of cancer disappear after therapy, according to a ...

Rectosigmoid junction,” he said, referring to a zone where the rectum and colon meet. After surgery came chemotherapy. He did 10 rounds of infusions, 28 rounds of radiation and oral chemotherapy.

As for all 49 patients with rectal cancer who participated in the study, “there was no evidence of cancer after immunotherapy,” according to the Memorial Sloan Kettering Cancer Center release.

Maureen Sideris, 71, was one of those patients. The New York resident was diagnosed with gastroesophageal junction cancer in 2022 after she noticed it was difficult for her to swallow and digest food.

Results: Of the 310 eligible patients, 14% received neither chemo nor RT, 13% received chemo or RT, and 73% received both. Receipt of chemo and RT was associated with younger age, stage III, ...

New research shows 92% of cancer patients stayed cancer-free for two ... Among patients with rectal cancer, ... esophageal, stomach, and gastroesophageal junction cancers, 92 percent had no signs ...

Rectosigmoid junction,” he said, referring to a zone where the rectum and colon meet. After surgery came chemotherapy. He did 10 rounds of infusions, 28 rounds of radiation and oral chemotherapy.

Among patients with rectal cancer, ... esophageal, stomach, and gastroesophageal junction cancers, 92 percent had no signs of disease after two years. Maureen Sideris, 71, ...